Pharma RSS Digest - 2026-05-18

Overview

The May 18, 2026 pharma landscape shows continued momentum in AI-assisted drug discovery, with Harbour BioMed's first AI-designed candidate delivering preclinical body composition data that could position it competitively against established obesity treatments. Meanwhile, contract manufacturing relationships are deepening, as exemplified by LOTTE Biologics' expanded role with Ottimo Pharma, suggesting biotech sponsors are increasingly willing to invest in CDMO partnerships ahead of clinical readouts. The ACVR2A/2B pathway validated by prior bimagrumab data is now attracting next-generation entrants, while the broader metabolic space remains a focal point for combination strategies addressing GLP-1 limitations. Manufacturing capacity and process development capabilities are becoming differentiators as complex biologics advance through clinical pipelines.

Key Developments

Harbour BioMed's LET003 Delivers Preclinical Body Composition Data in Obesity

Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

Harbour BioMed announced preclinical results for LET003, its first AI-designed monoclonal antibody candidate targeting the ACVR2A/2B pathway. In obesity models, LET003 combined with semaglutide reduced fat mass by 76% versus vehicle and 34.7% versus semaglutide alone, while lean mass increased 5.7% compared to semaglutide monotherapy. Pharmacokinetic testing showed significantly slower blood clearance than comparators, and dose-ranging studies demonstrated LET003 at 5 mg/kg achieved lean mass effects comparable to bimagrumab at 15 mg/kg. The company plans to advance LET003 into clinical development for obesity treatment.

LOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma

The data provide a proof-of-concept for the Hu-mAtrIx AI platform and establish a differentiated profile against the benchmark bimagrumab, particularly given the 10-fold potency differential and favorable pharmacokinetics that could support lower or less frequent dosing. The lean mass preservation angle addresses a known limitation of GLP-1 only approaches, potentially expanding the addressable patient population. However, preclinical mouse and monkey data require careful translation expectations, and the competitive landscape for ACVR2A/2B inhibitors remains active with other programs likely in development. Watch for the company's IND timeline and initial clinical study design, particularly how they plan to position LET003 relative to existing GLP-1-based regimens.

LOTTE Biologics Expands Manufacturing Partnership with Ottimo Pharma

LOTTE Biologics has expanded its agreement with Ottimo Pharma to include commercial process development and characterization activities for OTP-01, a PD-1/VEGFR2 biparatopic antibody. The work will be conducted at Lotte's Syracuse Bio Campus in New York. The original manufacturing agreement was signed in June 2025, and Ottimo Pharma recently initiated a Phase 1/2a study for OTP-01 with what it describes as industry-leading speed. LOTTE operates as a pure-play CDMO with dual manufacturing sites in the U.S. and South Korea.

The expansion reflects growing client confidence in Lotte's CDMO capabilities as OTP-01 advances towards commercialization, and signals a broader trend of biotech sponsors outsourcing not just manufacturing but also process development to specialized partners. Lotte's dual-site strategy provides supply chain redundancy that global biotech clients increasingly require. The inclusion of commercial process development activities suggests Ottimo is investing ahead of clinical data to compress timeline to market. Watch for Phase 1/2a enrollment progress and any updates on manufacturing scale-up plans, as well as further evidence of Lotte's ability to convert early-stage partnerships into long-term commercial relationships.

Watchlist

• Harbour BioMed (HKEX: 02142) - LET003 IND filing timeline and initial clinical trial protocol
• CDMO sector capacity utilization trends as complex biologics programs advance through 2026
• Competitive landscape for ACVR2A/2B inhibitors entering obesity development